Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Combined COVID–flu vaccines are coming: Moderna jab clears major test

First large trial suggests mRNA drug gives better protection from SARS-CoV-2 and influenza viruses than single-target shots.
  1. Freda Kreier
    View author publications

    You can also search for this author in PubMed  Google Scholar

A single vaccine has been shown to protect people from both SARS-CoV-2 and influenza viruses — and provoked a higher immune response than vaccines that target one or the other, the pharmaceutical company Moderna has announced.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-024-02121-1

Updates & Corrections

  • Clarification 08 October 2024: This article was amended to clarify statements about the vaccine’s effects.

References

  1. Arevalo, C. P. et al. Science 378, 899–904 (2022).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links